Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers
NCT ID: NCT06133790
Last Updated: 2024-02-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2024-01-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Some studies show a difference in the expression of certain genes within the two groups of tumors (HPV+ and HPV-) including some that confer sensitivity to certain chemotherapies and others to radiotherapy. However, patients with HPV+ Head and Neck cancers are treated according to the same referential as HPV- Head and Neck cancers. There is therefore a real need for studies identifying predictive markers in order to be able to offer patients a more effective suitable and less invasive treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Papillomavirus and Oropharynx Carcinoma
NCT00918710
Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer
NCT03788785
HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors
NCT04979000
The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study
NCT02126189
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
NCT01358097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Squamous cell cancers of the head and neck are classically correlated with risk factors linked to excessive consumption of alcohol and tobacco and have a rather poor prognosis (mainly HPV (Human Papilloma Virus) negative patients).
However, the incidence of Head and Neck cancers in patients without alcohol-smoking risk factor has continued to increase in recent years, in relation to more and more frequent HPV contamination. Evolution of oral sexual practices seems to be one of the explanations for the progression of these cases of oropharyngeal squamous cell carcinoma and oral cavity HPV positive.
Some studies show a difference in the expression of certain genes within the two groups of tumors (HPV+ and HPV-) including some that confer sensitivity to certain chemotherapies (CCND1, TYMS) and others to radiotherapy (RBBP4). However, patients with HPV+ Head and Neck cancers are treated according to the same referential as HPV- Head and Neck cancers. There is therefore a real need for studies identifying predictive markers in order to be able to offer patients a more effective suitable and less invasive treatment. This is the context of this research project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HPV + Group
Patients with positive HPV diagnosis
PCR - Immunohistochemistry - Immunolabelling
Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
HPV - Group
Patients with negative HPV diagnosis
PCR - Immunohistochemistry - Immunolabelling
Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCR - Immunohistochemistry - Immunolabelling
Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary tumor for which a biopsy or excision is required available and sufficient to carry out molecular analysis
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GCS Ramsay Santé pour l'Enseignement et la Recherche
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jérôme PARIS, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital privé de Clairval
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Privé Clairval
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A00936-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.